Holen Sie sich die Stockscreener-App
30.94
4.53%
1.34
Schlusskurs vom Vortag:
$29.60
Offen:
$29.5
24-Stunden-Volumen:
342.21K
Relative Volume:
0.77
Marktkapitalisierung:
$1.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.58%
1M Leistung:
+12.80%
6M Leistung:
+164.90%
1J Leistung:
+47.54%
1-Tages-Spanne:
$29.04
$31.21
1-Wochen-Bereich:
$26.73
$31.21
52-Wochen-Spanne:
$5.485
$31.21
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
30.94 | 1.43B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com India
Should I hold or sell Oruka Therapeutics Inc. stock in 2025Market Movement Recap & AI Based Buy and Sell Signals - Newser
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Will Oruka Therapeutics Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - Newser
How Oruka Therapeutics Inc. (HQ1) stock performs during market turbulence2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
What valuation ratios show for Oruka Therapeutics Inc. (HQ1) stock2025 Support & Resistance & Reliable Breakout Forecasts - Newser
Will Oruka Therapeutics Inc. (HQ1) stock hit analyst forecastsWeekly Profit Analysis & Breakout Confirmation Alerts - Newser
Franklin Resources Inc. Purchases 292,421 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
ORKA-001 Advances Toward Yearly Dosing - Dermatology Times
How Investors Are Reacting To Oruka Therapeutics (ORKA) Once-Yearly Psoriasis Treatment Breakthrough - sahmcapital.com
What drives Oruka Therapeutics Inc stock priceSupport Zone Identification & Rapid Capital Growth - earlytimes.in
Its Stock Has Paid Off Big Time For Oruka Therapeutics Inc - Setenews
Oruka Therapeutics stock hits 52-week high at 30.29 USD By Investing.com - Investing.com Australia
Oruka Therapeutics stock hits 52-week high at 30.29 USD - Investing.com
Does Oruka Therapeutics Inc. stock trade at a discount to peersJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com
Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Can Oruka Therapeutics Inc. (HQ1) stock hit consensus price targetsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock rise with strong economyRate Cut & High Accuracy Trade Signal Alerts - newser.com
Is Oruka Therapeutics Inc. stock attractive for income investorsQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-19 21:53:09 - newser.com
Can Oruka Therapeutics Inc. (HQ1) stock surprise with quarterly resultsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can Oruka Therapeutics Inc. stock sustain market leadershipEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Published on: 2025-11-19 17:15:05 - newser.com
Key metrics from Oruka Therapeutics Inc.’s quarterly dataPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Can momentum traders help lift Oruka Therapeutics Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock sustain dividend payoutsWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock attract long term capital inflowsDividend Hike & Safe Capital Growth Tips - newser.com
Why Oruka Therapeutics Inc. (HQ1) stock is trending on social mediaQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):